id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-355540-rlvzj2e5	Bodei, Lisa	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?	2020-08-17		.txt	text/plain	1569	73	40	Here, we discuss risk factors for COVID-19 severity with regard to peptide receptor radionuclide therapy (PRRT), focusing on the question of whether lymphopenia increases risk of infection-related morbidity. At this time, it is not known if the moderately compromised immune response (predominantly involving B lymphocytes) associated with PRRT results in an impaired capacity to defend against subsequent severe acute respiratory syndrome coronavirus 2. Consequently, there is no clear theoretic indication that PRRT places patients at significantly greater risk of acquiring COVID-19 or developing more severe infection-related complications. The potential risks of PRRT in patients with progressive neuroendocrine tumor during the COVID-19 pandemic need to be considered in the context of the relative risks and benefits of other available therapies. Although available data are scarce, we agree that, for now, PRRTrelated lymphopenia does not appear to constitute a strong risk factor for acquiring COVID-19 infection or for developing severe complications. Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE and 90 Y-DOTATOC	./cache/cord-355540-rlvzj2e5.txt	./txt/cord-355540-rlvzj2e5.txt